R-COMP 21 for frail elderly patients with aggressive B-cell non-Hodgkin lymphoma: A pilot study

References

• Brincker H, Pedersen N T, Bendix-Hansen K, Johansen P. Non-Hodgkin's lymphoma subtypes over time in an unselected population of 646 patients: a study of clinico-pathological data and incidence based on a review using the REAL-classification. Leuk Lymphoma 2000; 39: 531–541
   PubMed Web of Science ®Google Scholar
• Devesa S S, Fears T. Non-Hodgkin's lymphoma time trends: United States and international data. Cancer Res 1992; 52: 5432–5440
   PubMed Web of Science ®Google Scholar
• Cartwright R, Brincker H, Carli P M, Clayden D, Coebergh J W, Jack A, et al. The rise in incidence of lymphomas in Europe 1985–1992. Eur J Cancer 1999; 35: 627–633
   PubMed Web of Science ®Google Scholar
• Muller A, Ihorst G, Mertelsmann R, Engelhardt M. Epidemiology of non-Hodgkin's lymphoma (NHL): trends, geographic distribution and etiology. Ann Haematol 1999; 84: 1–12
   Web of Science ®Google Scholar
• The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993; 329: 987–994
   PubMed Web of Science ®Google Scholar
• The Non-Hodgkin's Lymphoma Classification Project. Effect of age on the characteristics and clinical behavior of non-Hodgkin's lymphoma patients. Ann Oncol 1997; 8: 973–978
   PubMed Web of Science ®Google Scholar
• Bastion Y, Blay J Y, Divine M, Brice P, Bordessoule D, Sebban C. Elderly patients with aggressive non-Hodgkin's lymphoma: disease presentation, response to treatment, and survival-a Groupe d'Etude des Lymphomes de l'Adulte study on 453 patients older than 69 years. J Clin Oncol 1997; 15: 2945–2953
   PubMed Web of Science ®Google Scholar
• Vose J M, Armitage J O, Weisenburger D D, Bierman P J, Sorensen S, Hutchins M. The importance of age in survival of patients treated with chemotherapy for aggressive non-Hodgkin's lymphoma. J Clin Oncol 1988; 6: 1838–1844
   PubMed Web of Science ®Google Scholar
• Fisher R I, Gaynor E R, Dahlberg S, Oken M M, Grogan T M, Mize E M. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993; 328: 1002–1006
   PubMed Web of Science ®Google Scholar
• Gordon L I, Harrington D, Andersen J, Colgan J, Glick J, Neiman R. Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma. N Engl J Med 1992; 327: 1342–1349
   PubMed Web of Science ®Google Scholar
• Jerkeman M, Anderson H, Cavallin-Ståhl E, Dictor M, Hagberg H, Johnson A, et al. CHOP versus MACOP-B in aggressive lymphoma – a Nordic Lymphoma Group randomised trial. Ann Oncol 1999; 10: 1079–1086
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235–242
   PubMed Web of Science ®Google Scholar
• Armitage J O, Potter J F. Aggressive chemotherapy for diffuse histiocytic lymphoma in the elderly: increased complications with advancing age. J Am Geriatr Soc 1984; 32: 269–273
   PubMed Web of Science ®Google Scholar
• Sonneveld P, de Ridder M, van der Lelie H, Nieuwenhuis K, Schouten H, Mulder A, et al. Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy. J Clin Oncol 1995; 13: 2530–2539
   PubMed Web of Science ®Google Scholar
• Meyer R, Browman G, Samosh M, Benger A, Bryant-Lukosius D, Wilson W, et al. Randomized phase II comparison of standard CHOP with weekly CHOP in elderly patients with non-Hodgkin's lymphoma. J Clin Oncol 1995; 13: 2386–2393
   PubMed Web of Science ®Google Scholar
• Conley B A, Egorin M J, Whitacre M T, Carter D C, Zuhowski E G, Van Echo D A. Phase I and pharmacokinetic trial of liposome encapsulated doxorubicin. Cancer Chemother Pharmacol 1993; 33: 107–112
   PubMed Web of Science ®Google Scholar
• Cowens J W, Creaven P J, Greco W R, Brenner D E, Tung Y, Ostro M, et al. Initial clinical (Phase I) trial of Myocet (doxorubicin encapsulated in liposomes). Cancer Res 1993; 53: 2796–2802
   PubMed Web of Science ®Google Scholar
• Ostro M J. Liposomes: from the bench to the marketplace—doxorubicin as an example. Liposomes in the Therapy of Infectious Diseases and Cancer, I J Fidler, G Lopez-Berestein. New York, Alan Liss 1989; 155–163
   Google Scholar
• Mayer L D, Bally M B, Cullis P R, Wilson S L, Emerman J T. Comparison of free and liposome-encapsulated doxorubicin tumor drug uptake and antitumor efficacy in the SC115 murine mammary tumor. Cancer Lett 1990; 53: 183–190
   PubMed Web of Science ®Google Scholar
• Batist G, Ramakrishnan G, Rao C S, Chandrasekharan A, Gutheil J, Guthrie T, et al. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J Clin Oncol 2001; 19: 1444–1454
   PubMed Web of Science ®Google Scholar
• Balducci L, Extermann M. Management of cancer in the older person: a practical approach. Oncologist 2000; 5: 224–237
   PubMedGoogle Scholar
• Cheson B D, Horning S J, Coiffier B. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 1999; 17: 1244–1253
   PubMed Web of Science ®Google Scholar
• Fleming T R. One-sample multiple testing procedure for Phase II clinical trials. Biometrics 1982; 38: 143–151
   PubMed Web of Science ®Google Scholar
• Harris N L, Jaffe E S, Stein H. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361–1392
   PubMed Web of Science ®Google Scholar
• Carbone P P, Kaplan H S, Musshoff K. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res 1971; 31: 1860–1861
   PubMed Web of Science ®Google Scholar
• Levine A M, Tulpule A, Espina B, Sherrod A, Boswell W D, Lieberman R D, et al. Liposome-encapsulated doxorubicin in combination with standard agents (cyclophosphamide, vincristine, prednisone) in patients with newly diagnosed AIDS-related non-Hodgkin's lymphoma: results of therapy and correlates of response. J Clin Oncol 2004; 22: 2662–2670
   PubMed Web of Science ®Google Scholar
• Tulpule A, Espina B M, Berman N, Buchanan L H, Smith D L, Sherrod A, et al. Phase I/II trial of nonpegylated liposomal doxorubicin, cyclophosphamide, vincristine, and prednisone in the treatment of newly diagnosed aggressive non-Hodgkin's lymphoma. Clin Lymphoma Myeloma 2006; 7: 59–64
   PubMedGoogle Scholar
• Rigacci L, Mappa S, Nassi L, Alterini R, Carrai V, Bernardi F, Bosi A. Liposome-encapsulated doxorubicin in combination with cyclophosphamide, vincristine, prednisone and rituximab in patients with lymphoma and concurrent cardiac diseases or pre-treated with anthracyclines. Hematol Oncol 2007; 25: 198–203
   PubMed Web of Science ®Google Scholar